Revisión clínica | 02 ABR 14

Síndrome nefrótico en adultos

Todavía existen dudas sobre su estudio y manejo por la falta de estudios aleatorizados, revisiones sistemáticas y guías de recomendaciones.
27
89
Autor/a: Dres. Richard P Hull and David J A Goldsmith. BMJ 2008;336;1185-1189
INDICE:  1.  | 2. Referencias
Referencias

1.    Cameron JS, Hicks J. The origins and development of the concept of a “nephrotic syndrome.” Am J Nephrol 2002;22:240-7.
2.    Llach F. Thromboembolic complications in the nephrotic syndrome. Coagulation abnormalities, renal vein thrombosis and other conditions. Postgrad Med 1984;76:111-4, 116-8, 121-3.
3.    National Collaborating Centre for Chronic Conditions. Chronic kidney disease: early identification and management of adults with chronic kidney disease in primary and secondary care. Draft for consultation: full guideline published 10 March 2008. www.nice.org.uk/nicemedia/pdf/CKDConsFullGuideline.pdf.
4.    Jayawardene SA, Scoble JF, Goldsmith DJ. Nephrotic syndrome: more than just oedema. Int J Clin Pract 2002;56:129-31.
5.    IchikawaI,RennkeHG,Hoyer JR,BadrKF,Schor N,TroyJL,etal.Role for intrarenalmechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 1983;71:91-103.
6.    Buerkert J, Martin DR, Trigg D, Simon EE. Sodium handling by deep nephrons and the terminal collecting duct in glomerulonephritis. Kidney Int 1991;39:850-7.
7.    Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30:621-31.
8.    KorbetSM,GenchiRM,Borok RZ,SchwartzMM. The racialprevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996;27:647-51.
9.    Orth SR, Ritz E. The nephrotic syndrome.N Engl J Med 1998;338:1202-11.
10.    Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998;316:504-9.
11.    Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006;118:397-407.
12.    Parag KB, Somers SR, Seedat YK, Byrne S, Da Cruz CM, Kenoyer G. Arterial thrombosis in nephrotic syndrome. Am J Kidney Dis 1990;15:176-7.
13.    Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 1993;63:249-54.
14.    Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 1980;69:819-27.
15.    Wagoner RD, Stanson AW, Holley KE, Winter CS. Renal vein thrombosisin idiopathicmembranousglomerulopathyandnephrotic syndrome: incidence and significance. Kidney Int 1983;23:368-74.
16.    Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalizedwith nephrotic syndrome. Am J Med 2008;121:226-30.
17.    Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, et al.High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008;117:224-30.
18.    SarasinFP,Schifferli JA.Prophylacticoralanticoagulationinnephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994;45:578-85.
19.    Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007;18:2221-5.
20.    KulshresthaS,GrieffM,NavaneethanSD. Interventions forpreventing thrombosis in adults and children with nephrotic syndrome (protocol). Cochrane Database Syst Rev 2006;(2):CD006024.
21.    Charlesworth JA, Gracey DM, Pussell BA. Adult nephrotic syndrome: non-specific strategies for treatment. Nephrology (Carlton) 2008;13:45-50.
22.    Li YJ, Xie C, Xia ZM. Risk factors for infection in adult nephritic syndrome. Chinese J Nephrol 1996:12:76-8.
23.    OgiM, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Takaeda M, et al.  Risk factors for infection andimmunoglobulin replacement therapy in adult nephrotic syndrome. AmJ Kidney Dis 1994;24:427-36.
24.    Wu HM, Tang JL, Sha ZH, Cao L, Li YP. Interventions for preventing infection in nephrotic syndrome. Cochrane Database Syst Rev 2004;(2):CD003964.
25.    Koomans HA. Pathophysiology of acute renal failure in idiopathic nephrotic syndrome.Nephrol Dial Transplant 2001;16:221-4.
26.    Dorhout Mees EJ. Does it make sense to administer albumin to the patient with nephrotic oedema? Nephrol Dial Transplant 1996;11:1224-6.
27.    Ruggenenti P, Perusa A, Mosconi L, Pisone R, Remuzzi G. Urinary protein excretion is the best predictor of ESRF in non-diabetic chronic nephropathies. Kidney Int 1998;53:1209-16.
28.    Locatelli F, Marcelli D, Cornelli M, Alberti D, Graziani G, Buccianti G, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group.Nephrol Dial Transplant 1996;11:461-7.
29.    Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a metaanalysis of comparative trials. Nephrol Dial Transplant 1995;10:1963-74.
30.    Randomised controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-63.
31.    Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.
32.    Tsouli SG, Liberopoulos EN, Kiortsis DN, Mikhailidis DP, Elisaf MS. Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptorblockers: a reviewof the current evidence. J Cardiovasc Pharmacol Ther 2006;11:1-15.
33.    Wheeler DC, Bernard DB. Lipid abnormalities in the nephritic syndrome: cause, consequences and treatment. Am J Kid Dis 1994;23:331-46.
34.    Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638-42.
35.    Crew RJ, Radhakrishnan J, Appel G. Complications of the nephritic syndrome and their treatment. Clin Nephrol 2004;62:245-59.
36.    Fried LF, Orchard TJ, Kasiske BL; for the Lipids and Renal Disease Progression Meta-analysis Study Group. Effect of lipid reduction on the progression of renal disease: a metanalysis. Kidney Int 2001;59:260-9.
37.    TonelliM,Moyé L, Sacks F, Cole T, CurhamG. Effect of pravastatin on loss of renal function in patients with moderate chronic renal insufficiency and cardiovascular disease. J AmSoc Nephrol 2003;14:1605-13.
38.    GuarneiriGF, ToigoG,Situlin R, CarraroM, TamaroG, Lucchesli A, et al. Nutritional status in patients on long term low-protein diet or with nephrotic syndrome. Kidney Int Suppl 1989;27:S195-200.
 

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021